Asciminib Stands out As the Superior Tyrosine Kinase Inhibitor to Combine with Anti-Cd20 Monoclonal Antibodies for the Treatment of CD20+ Philadelphia-positive B-cell Precursor Acute Lymphoblastic Leukemia in Preclinical Models
Haematologica(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined